Author's Accepted Manuscript Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection after Induction Chemotherapy for Good Risk NonSeminomatous Germ Cell Tumors Shilajit D. Kundu, Darren R. Feldman, Brett S. Carver, Amit Gupta, George J. Bosl, Robert J. Motzer, Dean F. Bajorin, Joel Sheinfeld PII: DOI: Reference:
S0022-5347(14)04254-2 10.1016/j.juro.2014.08.081 JURO 11737
To appear in: The Journal of Urology Accepted Date: 11 August 2014 Please cite this article as: Kundu SD, Feldman DR, Carver BS, Gupta A, Bosl GJ, Motzer RJ, Bajorin DF, Sheinfeld J, Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection after Induction Chemotherapy for Good Risk Non-Seminomatous Germ Cell Tumors, The Journal of Urology® (2014), doi: 10.1016/j.juro.2014.08.081. DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain. All press releases and the articles they feature are under strict embargo until uncorrected proof of the article becomes available online. We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date.
ACCEPTED MANUSCRIPT
RI PT
Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection after Induction Chemotherapy for Good Risk Non-Seminomatous Germ Cell Tumors
Shilajit D. Kundu1, Darren R. Feldman2, Brett S. Carver2, Amit Gupta3, George J. Bosl2, Robert J. Motzer2, Dean F. Bajorin2, Joel Sheinfeld2
Department of Urology, Northwestern Medicine, Chicago, IL
SC
1
2
M AN U
Urology Service, Department of Surgery, and the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
3
Department of Urology, University of Iowa Carver College of Medicine, Iowa City, Iowa
EP
TE D
Supported by: The Sidney Kimmel Center for Prostate and Urologic Cancers and a T32 grant from the National Institute of Health (T32 CA082088) and The Capri Foundation
AC C
Corresponding Author: Joel Sheinfeld, MD 1275 York Ave New York, NY 10065 [email protected]
1
ACCEPTED MANUSCRIPT
Abstract Purpose: Patients with good risk nonseminomatous germ cell tumors receive induction chemotherapy with either 4 cycles of etoposide and platinum (EPx4) or three cycles of
RI PT
bleomycin, etoposide, and platinum (BEPx3). We report the histologic results at postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) after induction chemotherapy in patients treated either with EP or BEP for good risk NSGCT.
SC
Materials and Methods: PC-RPLND was performed in 579 patients following induction chemotherapy. Five-hundred five patients were treated with EPx4 and 74 patients were
M AN U
treated with BEPx3 or BEPx4. Clinical and pathologic features are reported. Results: No difference in the frequency of viable residual cancer was observed between BEP and EP (5% vs 6%, respectively, P=NS). Teratoma was more prevalent in the BEP group vs. EP (57% vs. 34%, respectively, p
S0022-5347(14)04254-2 10.1016/j.juro.2014.08.081 JURO 11737
To appear in: The Journal of Urology Accepted Date: 11 August 2014 Please cite this article as: Kundu SD, Feldman DR, Carver BS, Gupta A, Bosl GJ, Motzer RJ, Bajorin DF, Sheinfeld J, Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection after Induction Chemotherapy for Good Risk Non-Seminomatous Germ Cell Tumors, The Journal of Urology® (2014), doi: 10.1016/j.juro.2014.08.081. DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain. All press releases and the articles they feature are under strict embargo until uncorrected proof of the article becomes available online. We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date.
ACCEPTED MANUSCRIPT
RI PT
Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection after Induction Chemotherapy for Good Risk Non-Seminomatous Germ Cell Tumors
Shilajit D. Kundu1, Darren R. Feldman2, Brett S. Carver2, Amit Gupta3, George J. Bosl2, Robert J. Motzer2, Dean F. Bajorin2, Joel Sheinfeld2
Department of Urology, Northwestern Medicine, Chicago, IL
SC
1
2
M AN U
Urology Service, Department of Surgery, and the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
3
Department of Urology, University of Iowa Carver College of Medicine, Iowa City, Iowa
EP
TE D
Supported by: The Sidney Kimmel Center for Prostate and Urologic Cancers and a T32 grant from the National Institute of Health (T32 CA082088) and The Capri Foundation
AC C
Corresponding Author: Joel Sheinfeld, MD 1275 York Ave New York, NY 10065 [email protected]
1
ACCEPTED MANUSCRIPT
Abstract Purpose: Patients with good risk nonseminomatous germ cell tumors receive induction chemotherapy with either 4 cycles of etoposide and platinum (EPx4) or three cycles of
RI PT
bleomycin, etoposide, and platinum (BEPx3). We report the histologic results at postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) after induction chemotherapy in patients treated either with EP or BEP for good risk NSGCT.
SC
Materials and Methods: PC-RPLND was performed in 579 patients following induction chemotherapy. Five-hundred five patients were treated with EPx4 and 74 patients were
M AN U
treated with BEPx3 or BEPx4. Clinical and pathologic features are reported. Results: No difference in the frequency of viable residual cancer was observed between BEP and EP (5% vs 6%, respectively, P=NS). Teratoma was more prevalent in the BEP group vs. EP (57% vs. 34%, respectively, p
